Core Viewpoint - The stock price of Shenqi Pharmaceutical has shown fluctuations, with a recent decline of 2.12%, while the company has experienced a year-to-date increase of 2.98% in stock price [1][2]. Group 1: Stock Performance - As of November 17, Shenqi Pharmaceutical's stock price is 6.91 CNY per share, with a market capitalization of 3.69 billion CNY [1]. - The stock has increased by 3.91% over the last five trading days and 9.68% over the last 20 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Shenqi Pharmaceutical reported a revenue of 1.398 billion CNY, a year-on-year decrease of 10.58%, and a net profit attributable to shareholders of 50.30 million CNY, down 15.25% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 366 million CNY, with 187 million CNY distributed over the last three years [3]. Group 3: Business Overview - Shenqi Pharmaceutical, established on July 22, 1992, focuses on the research, production, and sales of pharmaceuticals, with its main revenue sources being specialty products (45.33%), anti-tumor drugs (27.73%), and traditional Chinese medicine (8.54%) [2]. - The company operates within the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, and is involved in various concept sectors including retail pharmacies and traditional Chinese medicine [2].

Core Viewpoint - The stock price of Shenqi Pharmaceutical has shown fluctuations, with a recent increase of 2.06% but a year-to-date decline of 4.17%, indicating potential volatility in the market [1][2]. Company Overview - Shenqi Pharmaceutical, established on July 22, 1992, and listed on August 20, 1992, is located at 128 Weihai Road, Shanghai. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The revenue composition of Shenqi Pharmaceutical includes: Other Specialty Products Series (43.60%), Antitumor Drug Series (25.86%), Traditional Chinese Medicine Cough Relief Series (12.09%), Chronic Disease Products Series (6.05%), Miao Medicine Strong Bone Series (4.58%), Skin Antibacterial Products (4.37%), Classic Nutritional Products Series (2.43%), and Shenqi Baby Medicine Series (1.00%) [2]. Financial Performance - For the first half of 2025, Shenqi Pharmaceutical reported a revenue of 961 million yuan, a year-on-year decrease of 13.47%, and a net profit attributable to shareholders of 32.81 million yuan, down 13.29% year-on-year [2]. - The company has distributed a total of 366 million yuan in dividends since its A-share listing, with 187 million yuan distributed over the past three years [3]. Market Activity - As of October 21, the stock price was 6.43 yuan per share, with a market capitalization of 3.434 billion yuan. The trading volume was 21.9066 million yuan, with a turnover rate of 0.72% [1]. - The net outflow of main funds was 550,800 yuan, with large orders buying 1.0123 million yuan (4.62%) and selling 1.5631 million yuan (7.14%) [1].

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-029 B 股 900904 B 股 神奇 B 股 1．主营业务分行业情况 单位：元 1 分行业 2025年 1-6月营业 收入 2025 年 1-6 月营 业成本 毛利率 （%） 营业收 入比上 期增减 （%） 营业成 本比上 期增减 （%） 毛利率 比上年 增减百 分点 一、医药制造 551,106,207.88 145,299,577.01 73.63 -17.88 -22.39 1.53 二、医药商业 409,743,638.84 365,475,382.80 10.80 -6.73 -7.94 1.17 合计 960,849,846.72 510,774,959.81 46.84 -13.47 -12.57 -0.54 2．主营业务分类情况 单位：元 分产品 营业收入 营业成本 毛利率 （%） 营业收入 比上年增 减（%） 营业成本 比上年增 减（%） 毛利率 比上年 增减百 分点 抗肿瘤药系列 245,469,455.95 27,664,258.77 88.73 -6.54 -13.13 0.85 皮肤外用抗菌 系列 58 ...

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-010 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2025 年第一季度主要运营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、运营数据 1．主营业务分行业情况 单位：元 1 分行业 2025年 1-3月营业 收入 2025 年 1-3 月营 业成本 毛利率 （%） 营业收 入比上 年同期 增减（%） 营业成 本比上 年同期 增减（%） 毛利率 比上年 同期增 减（%） 一、医药制造 274,211,549.66 72,209,058.64 73.67 -21.05 -15.26 -1.80 二、医药商业 205,715,284.98 183,258,206.18 10.92 -9.47 -11.36 1.91 合计 479,926,834.64 255,467,264.82 46.77 -16.47 -12.50 -2.41 2．主营业务分类情况 单位：元 分产品 营业收入 营业成本 毛利率 （% ...